HRP20030109A2 - Highly purified simvastatin compositions - Google Patents

Highly purified simvastatin compositions Download PDF

Info

Publication number
HRP20030109A2
HRP20030109A2 HR20030109A HRP20030109A HRP20030109A2 HR P20030109 A2 HRP20030109 A2 HR P20030109A2 HR 20030109 A HR20030109 A HR 20030109A HR P20030109 A HRP20030109 A HR P20030109A HR P20030109 A2 HRP20030109 A2 HR P20030109A2
Authority
HR
Croatia
Prior art keywords
group
simvastatin
lovastatin
formula
amine
Prior art date
Application number
HR20030109A
Other languages
English (en)
Croatian (hr)
Inventor
Csaba Szabo
Ferenc Korodi
Szabolcs Salyi
Istvan Melczer
Leonov David
Original Assignee
Plus Chemicals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plus Chemicals B.V. filed Critical Plus Chemicals B.V.
Publication of HRP20030109A2 publication Critical patent/HRP20030109A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20030109A 2000-07-27 2001-07-26 Highly purified simvastatin compositions HRP20030109A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22111200P 2000-07-27 2000-07-27
PCT/US2001/023525 WO2002009697A1 (en) 2000-07-27 2001-07-26 Highly purified simvastatin compositions

Publications (1)

Publication Number Publication Date
HRP20030109A2 true HRP20030109A2 (en) 2005-02-28

Family

ID=22826406

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030109A HRP20030109A2 (en) 2000-07-27 2001-07-26 Highly purified simvastatin compositions

Country Status (20)

Country Link
US (1) US6686481B2 (cs)
EP (1) EP1303268A4 (cs)
JP (1) JP2004505045A (cs)
KR (1) KR100542094B1 (cs)
CN (1) CN1446088A (cs)
AU (2) AU2001282981B2 (cs)
CA (1) CA2419206A1 (cs)
CZ (1) CZ2003554A3 (cs)
HR (1) HRP20030109A2 (cs)
HU (1) HUP0302963A3 (cs)
IL (1) IL154068A0 (cs)
IS (1) IS6698A (cs)
MX (1) MXPA03000748A (cs)
NZ (1) NZ524418A (cs)
PL (1) PL365691A1 (cs)
RU (1) RU2275909C2 (cs)
SK (1) SK2172003A3 (cs)
WO (1) WO2002009697A1 (cs)
YU (1) YU101402A (cs)
ZA (1) ZA200300344B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100435078B1 (ko) * 2002-02-08 2004-06-09 종근당바이오 주식회사 심바스타틴의 정제방법
KR100502834B1 (ko) * 2002-03-25 2005-07-20 보령제약 주식회사 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
WO2004071456A2 (en) * 2003-02-11 2004-08-26 Plus Chemicals, B.V. Process for preparing simvastatin having controlled ranges of simvastatin dimer content
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
AU2007245410A1 (en) * 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
HUE027872T2 (en) 2006-05-03 2016-11-28 Msn Laboratories Private Ltd A novel process for statins and their pharmaceutically acceptable salts
BRPI0711889B8 (pt) * 2006-05-24 2021-05-25 Univ California método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
JP2009114121A (ja) * 2007-11-06 2009-05-28 Kaneka Corp シンバスタチンの製造方法
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN103864611B (zh) * 2013-12-24 2015-11-11 深圳华润九新药业有限公司 一种辛伐他汀羟基酸化物的制备方法、组合物、组合物的制备方法及其应用
CN103755562B (zh) * 2013-12-24 2015-11-18 深圳华润九新药业有限公司 一种洛伐他汀羟基酸化物的制备方法、组合物、组合物的制备方法及其应用
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4293496A (en) 1980-02-04 1981-10-06 Merck & Co., Inc. 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5159104A (en) 1991-05-01 1992-10-27 Merck & Co., Inc. Process to simvastatin ester
US5393893A (en) 1993-11-08 1995-02-28 Apotex, Inc. Process for producing simvastatin and analogs thereof
JP2001508782A (ja) * 1997-01-28 2001-07-03 プラス ケミカルズ ベスローテン フェンノートシャップ 新規中間体を経る半合成スタチンの製法
SI9800057A (sl) 1998-02-26 1999-08-31 Krka, Tovarna Zdravil, D.D. Postopek za pripravo simvastatina in njegovih derivatov
EP0940395A1 (en) 1998-03-05 1999-09-08 Synthon B.V. Process for producing simvastatin and/or its derivatives
NO991045L (no) * 1998-03-05 1999-09-06 Synthon Bv FremgangsmÕte ved fremstilling av simvastatin og/eller dets derivater

Also Published As

Publication number Publication date
HUP0302963A3 (en) 2004-03-01
US20020115712A1 (en) 2002-08-22
KR100542094B1 (ko) 2006-01-11
WO2002009697A1 (en) 2002-02-07
EP1303268A1 (en) 2003-04-23
CZ2003554A3 (cs) 2003-08-13
AU8298101A (en) 2002-02-13
PL365691A1 (en) 2005-01-10
CN1446088A (zh) 2003-10-01
HUP0302963A2 (hu) 2003-12-29
SK2172003A3 (en) 2003-06-03
JP2004505045A (ja) 2004-02-19
EP1303268A4 (en) 2006-08-09
KR20030047995A (ko) 2003-06-18
RU2275909C2 (ru) 2006-05-10
MXPA03000748A (es) 2004-06-25
AU2001282981B2 (en) 2004-08-05
IS6698A (is) 2003-01-24
ZA200300344B (en) 2004-01-21
NZ524418A (en) 2004-12-24
YU101402A (sh) 2006-01-16
IL154068A0 (en) 2003-07-31
US6686481B2 (en) 2004-02-03
CA2419206A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
KR100538674B1 (ko) 신규 중간체를 통한 반합성 스타틴의 제조 방법
HRP20030109A2 (en) Highly purified simvastatin compositions
IE83835B1 (en) (R-(R*R*))-2-(4-fluorophenyl)-BETA,DELTA-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
EP0325817B1 (en) Novel hmg-coa reductase inhibitors
AU2001282981A1 (en) Highly purified simvastatin compositions
JPH03163041A (ja) ４―置換　ＨＭＧ―ＣｏＡ　還元酵素抑制剤
CA2491051A1 (en) Atorvastatin calcium form vi or hydrates thereof
EP0323866B1 (en) Novel hmg-coa reductase inhibitors
AU606203B2 (en) Novel hmg-coa reductase inhibitors
CN101613284B (zh) 洛伐他汀、辛伐他汀和辛伐他汀-6-氧化物的硝基氧基衍生物及其制备方法
EP0410409A1 (en) 3,5-Dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US6541511B1 (en) Methyl analogs of simvastatin as novel HMG-CoA reductase inhibitors
US7425644B2 (en) Method of purifying pravastatin
HRP20040885A2 (en) Process for the preparation of 4-oxytetrahydropyran-2-ones
WO2006123355A2 (en) Novel statin derivatives
AU2002304343A1 (en) Methyl analogs of simvastatin as novel HMG-CoA reductase inhibitors
MXPA03009900A (es) Sintesis del acido [r-(r*, r*)]- (e)-2 (4-fluorofenil) -?, ?-dihidroxi- 5-(1-metiletil)- 3-fenil- 4-[(fenilamino) carbonil]- 1h-pirrol -hept-6 -enoico.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060710

Year of fee payment: 6

OBST Application withdrawn